CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date

References

• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 Jun;47(6):707–717.
   PubMed Web of Science ®Google Scholar
• Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol. 1998 Apr;43(4):465–471.
   PubMed Web of Science ®Google Scholar
• Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018 Jul;19(7):696–707.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):477–493.
   PubMed Web of Science ®Google Scholar
• Dhaeze T, Peelen E, Hombrouck A, et al. Circulating follicular regulatory T cells are defective in multiple sclerosis. J Immunol. 2015 Aug 1;195(3):832–840.
   PubMed Web of Science ®Google Scholar
• Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med. 1986 Jan 1;163(1):41–53.
   PubMed Web of Science ®Google Scholar
• Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. 1999 Feb;5(2):170–175.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol. 1981 Aug;10(2):149–158.
   PubMed Web of Science ®Google Scholar
• Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol. 1999 Aug;46(2):144–160.
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005 Jul;128(Pt 7):1667–1676.
   PubMed Web of Science ®Google Scholar
• Barbour C, Kosa P, Komori M, et al. Molecular-based diagnosis of multiple sclerosis and its progressive stage. Ann Neurol. 2017 Nov;82(5):795–812.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008 Jun;14(6):688–693.
   PubMed Web of Science ®Google Scholar
• Brandle SM, Obermeier B, Senel M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864–7869.
   PubMed Web of Science ®Google Scholar
• Brennan KM, Galban-Horcajo F, Rinaldi S, et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol. 2011 Sep 15;238(1–2):87–95.
   PubMed Web of Science ®Google Scholar
• Blauth K, Soltys J, Matschulat A, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol. 2015 Dec;130(6):765–781.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012 Jul 12;367(2):115–123.
   PubMed Web of Science ®Google Scholar
• Schirmer L, Srivastava R, Hemmer B. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler. 2014 Mar;20(3):271–279.
   PubMed Web of Science ®Google Scholar
• O‘Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol. 2005 Aug 1;175(3):1974–1982.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008 Oct;118(10):3420–3430.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Haber S, Rock KL. Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. J Immunol. 1985 Sep;135(3):1661–1667.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140–174.
   PubMedGoogle Scholar
• Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010 Jan;120(1):214–222.
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 Oct;125(4):1678–1685.
   PubMed Web of Science ®Google Scholar
• Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol. 2012 Jan;142(1):31–37.
   PubMed Web of Science ®Google Scholar
• Avasarala J. Anti-CD20 cell therapies in multiple sclerosis-a fixed dosing schedule for ocrelizumab is overkill. Drug Target Insights. 2017;11:1177392817737515.
   Web of Science ®Google Scholar
• Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017 Feb;16:41–50.
   PubMed Web of Science ®Google Scholar
• Moreno Torres I, Garcia-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017 Apr;17(4):359–371.
   PubMed Web of Science ®Google Scholar
• Meyer S, Evers M, Jansen JHM, et al. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol. 2018 Mar;180(6):808–820.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6): 676–690. 44958037465Reviews mode of action of the most prominent anti-CD20 mAbs.
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008 Jul 1;181(1):822–832.
   PubMed Web of Science ®Google Scholar
• Montalvao F, Garcia Z, Celli S, et al. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest. 2013 Dec;123(12):5098–5103.
   PubMed Web of Science ®Google Scholar
• Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005 Feb;62(2):258–264.
   PubMedGoogle Scholar
• Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006 Nov;180(1–2):63–70.
   PubMed Web of Science ®Google Scholar
• Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017 May 18;19(1):101.
   PubMedGoogle Scholar
• Garnock-Jones KP. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs. 2014 Mar;74(4):489–504.
   PubMed Web of Science ®Google Scholar
• Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017;1:1352458517740641.
   Google Scholar
• Silk M, Nantz E. Efficacy and safety of tabalumab in patients with relapsing-remitting multiple sclerosis: a randomized, double-blind, Placebo-Controlled Stud (P3.397). 2018;90(15Supplement): P3.397.
   Google Scholar
• Jakimovski D, Weinstock-Guttman B, Ramanathan M, et al. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opin Biol Ther. 2017 Sep;17(9):1163–1172.
   PubMed Web of Science ®Google Scholar
• Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018 Jan;83(1):13–26.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10(2): 183–203. Feb/Mar.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan;83(2):435–445.
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22–33. Jan-Feb.
   PubMed Web of Science ®Google Scholar
• Gasperi C, Stüve O, Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag. 2016;6(1):37–47.
   PubMed Web of Science ®Google Scholar
• Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005 Oct;62(10):1620–1623.
   PubMedGoogle Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008 Mar;63(3):395–400.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999 Oct 1;94(7):2217–2224.
   PubMed Web of Science ®Google Scholar
• Hawker K, O‘Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–471.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010 Jun 8;74(23):1860–1867.
   PubMed Web of Science ®Google Scholar
• Genentech. Rituxan highlights of prescribing information. [cited Oct 2018]. Available from: https://www.gene.com/download/pdf/rituxan_prescribing.pdf
   Google Scholar
• Gori T, Munzel T. A case of coronary hypersensitivity (Kounis) syndrome associated with mid-ventricular ballooning pattern, intracoronary thrombosis and troponin elevation. Int J Cardiol. 2011 Jun 16;149(3):377–378.
   PubMed Web of Science ®Google Scholar
• Kounis NG, Soufras GD, Tsigkas G, et al. Adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of Kounis syndrome. Oncoimmunology. 2014;3:e27987.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016 Nov 15;87(20):2074–2081. 47307546355Large Swedish registry cohort of MS patients treated with RTX.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011 Sep;68(9):1156–1164.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009 Nov;60(11):3225–3228.
   PubMed Web of Science ®Google Scholar
• Memon AB, Javed A, Caon C, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018;13(1):e0190425.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015 Oct;22(10):842–849.
   PubMed Web of Science ®Google Scholar
• Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017 May;152(6):1297–1309.
   PubMed Web of Science ®Google Scholar
• Marcinno A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018 Nov;5(6):e498.
   PubMed Web of Science ®Google Scholar
• Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr Opin Rheumatol. 2017 May;29(3):228–233.
   PubMed Web of Science ®Google Scholar
• Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018 May;265(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr;22(4):511–519.
   PubMed Web of Science ®Google Scholar
• De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford). 2012 May;51(5):833–840.
   PubMed Web of Science ®Google Scholar
• Christou EAA, Giardino G, Worth A, et al. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol. 2017 Nov 2;36(6):352–359.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Alping P, Piehl F, Frisell T. Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. ECTRIMS. Berlin: ECTRIMS Online Library; 2018 Oct 10.
   Google Scholar
• Langer-Gould A, Piehl F, Smith J, et al. Mortality rates in large US and Swedish rituximab-treated multiple sclerosis cohorts. ECTRIMS. Berlin: ECTRIMS Online Library; 2018 Oct 10.
   Google Scholar
• Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016 Jun;79(6):950–958.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013 Sep 1;72(9):1496–1502.
   PubMed Web of Science ®Google Scholar
• Luna G, Piehl F, Frisell T. Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. ECTRIMS. Berlin: ECTRIMS Online Library; 2018 Oct 11.
   Google Scholar
• Filippini G, Del Giovane C, Clerico M, et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev 2017 Apr 25;4:CD012200.
   Google Scholar
• Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol 2018 Mar 1;75(3):320-327.
   Google Scholar
• Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018 Aug;24(9):1224–1233.
   PubMed Web of Science ®Google Scholar
• Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017 Nov 16;8(1):12.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin‘s lymphoma. Blood. 1997 Sep 15;90(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011 Nov;68(11):1412–1420.
   PubMedGoogle Scholar
• Bonilla FA, Barlan I, Chapel H, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38–59.
   PubMed Web of Science ®Google Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018 5;May(3):e453.
   Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017 Oct;14(4):835–841.
   PubMed Web of Science ®Google Scholar
• Sabatino JJ Jr., Zamvil SS, Hauser SL. B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med. 2019 Feb;9:a032037 doi:10.1101/cshperspect.a032037.
   Web of Science ®Google Scholar
• Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018 Sep;32(9):883–890.
   PubMed Web of Science ®Google Scholar
• Frau J, Coghe G, Lorefice L, et al. New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatr Dis Treat. 2018;14:1093–1099.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 Nov 19;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Yan X, Jin K, Hung J. Statistical review and evaluation addendum. In: Administration USDoHaHSFaD. editor. Center for Drug Evaluation and Research. 2016 December 28 [cited 2019 April]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000StatR.pdf.
   Google Scholar
• Emery P, Rigby W, Tak PP, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9(2):e87379.
   PubMed Web of Science ®Google Scholar
• Hauser S, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis (S36.001). Neurology. 2018;90(15Supplement):S36.001.
   Google Scholar
• Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010 Sep;21(9):1870–1876.
   PubMed Web of Science ®Google Scholar
• Roche. Ocrelizumab and PML. Prescribing information. [cited 2019 April]. www.ocrelizumabinfo.global:Roche; 2019.
   Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Sep;58(9):2652–2661.
   PubMed Web of Science ®Google Scholar
• Alvarez E, Nair K, Shelton I, et al. Evaluating the tolerability and safety profile of switching from rituximab to ocrelizumab: infusion related reactions in relapsing forms of multiple sclerosis. ECTRIMS.Berlin: ECTRIMS Online Library; 2018 Oct 12.
   Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014 Feb 18;82(7):573–581.
   PubMed Web of Science ®Google Scholar
• Nguyen AL, Gresle M, Marshall T, et al. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. Br J Pharmacol. 2017 Jul;174(13):1895–1907.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018 May 15;90(20):e1805–e14.
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol. 2008 Feb;140(3):303–312.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006 Jul 1;177(1):362–371.
   PubMed Web of Science ®Google Scholar
• Reagan JL, Castillo JJ. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011 Feb;11(2):151–160.
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010 Aug;62(8):2227–2238.
   PubMed Web of Science ®Google Scholar
• Novartis. Arzerra highlights of prescribing information. [cited Aug 2016]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/arzerra.pdf
   Google Scholar
• Fox E. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS. Berlin: ECTRIMS Online Library; 2018 Oct 11.
   Google Scholar
• Trouvin AP, Jacquot S, Grigioni S, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015 Apr;180(1):11–18.
   PubMed Web of Science ®Google Scholar
• Cohen M, Romero G, Bas J, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017 Feb 15;373:335–338.
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337–341.
   PubMed Web of Science ®Google Scholar
• Stern JN, Yaari G, Vander Heiden JA, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med. 2014 Aug 6;6(248):248ra107.
   PubMed Web of Science ®Google Scholar